Hydroxychloroquine as a potential therapy for ANCA-associated vasculitis

Abstract

Antimalarial agents have been used to treat various autoimmune rheumatic diseases for over a century. Hydroxychloroquine is a safe, effective and inexpensive antimalarial drug with additional antithrombotic, cardioprotective, antimicrobial, and anti-neoplastic benefits. It has been used extensively in various diseases, especially systemic lupus erythematosus and rheumatoid arthritis; however, it has not been used in anti-neutrophil cytoplasmic antibody associated vasculitides (AAVs). There exists a significant unmet need for safe and inexpensive treatments for non-severe AAV or those with low-grade “grumbling” disease activity who do not warrant significant escalation of therapy but who remain at risk of disease flares and damage accumulation. Hydroxychloroquine may be an option to help fill this void. Although the mechanisms of action of Hydroxychloroquine are not fully understood, it interacts with various inflammatory mediators involved in the pathogenesis of AAV. Based on these benefits, along with the unmet need in AAV, we present evidence to support the use of Hydroxychloroquine as a potential therapy for AAV.

Keywords

Hydroxychloroquine / antimalarials / vasculitis / anti-neutrophilic cytoplasmic antibodies / autoimmune / immunomodulatory

References

[1] Kitching AR,Basu N.ANCA-associated vasculitis.Nat Rev Dis Primers2020;6:71

[2] Jennette JC,Bacon PA.2012 revised international Chapel Hill consensus conference nomenclature of vasculitides.Arthritis Rheum2013;65:1-11

[3] Hellmich B,Schirmer JH.EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.Ann Rheum Dis2024;83:30-47

[4] Tan JA,Chen W,Esdaile JM.Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies.Ann Rheum Dis2017;76:1566-74

[5] Robson J,Suppiah R.Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Ann Rheum Dis2015;74:177-84

[6] Basu N,Harper L.The characterisation and determinants of quality of life in ANCA associated vasculitis.Ann Rheum Dis2014;73:207-11

[7] Raimundo K,Kim G.Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States.J Rheumatol2015;42:2383-91

[8] Gill N,Yacyshyn E.Vasculitis patient journey: a scoping review of patient experiences with vasculitis.Clin Rheumatol2021;40:1697-708

[9] Jones RB,Hauser T.European Vasculitis Study GroupRituximab versus cyclophosphamide in ANCA-associated renal vasculitis.N Engl J Med2010;363:211-20

[10] Walsh M,Berden A.European Vasculitis Study GroupRisk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum2012;64:542-8

[11] Jayne DRW,Schall TJ.ADVOCATE Study GroupAvacopan for the treatment of ANCA-associated vasculitis.N Engl J Med2021;384:599-609

[12] Hellmich B,Gross WL.EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Ann Rheum Dis2007;66:605-17 PMCID:PMC2703775

[13] Sangle S,Hughes GR.Sulphamethoxazole-trimethoprim in the treatment of limited paranasal Wegener's granulomatosis.Rheumatology2002;41:589-90

[14] Tervaert JW. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.Curr Opin Rheumatol2018;30:388-94

[15] Monti S,Riboli M.The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis.Rheumatology2021;60:3553-64

[16] Gachelin G,Ferroni E,Chalmers I.Evaluating Cinchona bark and quinine for treating and preventing malaria.J R Soc Med2017;110:31-40 PMCID:PMC5305012

[17] Ben-Zvi I,Langevitz P.Hydroxychloroquine: from malaria to autoimmunity.Clin Rev Allergy Immunol2012;42:145-53 PMCID:PMC7091063

[18] Dima A,Chasset F,Arnaud L.Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.Ther Adv Musculoskelet Dis2022;14:1759720X211073001 PMCID:PMC8848057

[19] Goss A.Building the world's supply of quinine: dutch colonialism and the origins of a global pharmaceutical industry.Endeavour2014;38:8-18

[20] Payne JF.A postgraduate lecture on lupus erythematosus.J Clin Med1894;4:223-9

[21] Page F.Treatment of lupus erythematosus with mepacrine.Lancet1951;2:755-8

[22] Cornbleet T.Discoid lupus erythematosus treated with plaquenil.AMA Arch Derm1956;73:572-5

[23] Lewis HM.Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report.AMA Arch Derm1956;73:576-81

[24] Mullins JF,Wilson CJ.Plaquenil in the treatment of lupus erythematosus.J Am Med Assoc1956;161:879-81

[25] Manohar S,Rawat DS.4-aminoquinoline based molecular hybrids as antimalarials: an overview.Curr Top Med Chem2014;14:1706-33

[26] Rainsford KD,Clifford-Rashotte M.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Inflammopharmacology2015;23:231-69

[27] Schrezenmeier E.Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.Nat Rev Rheumatol2020;16:155-66

[28] Tett SE,Day RO.Bioavailability of hydroxychloroquine tablets in healthy volunteers.Br J Clin Pharmacol1989;27:771-9 PMCID:PMC1379804

[29] Costedoat-Chalumeau N,Huong DL,Piette JC.Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.Autoimmun Rev2005;4:111-5

[30] Russell MD,Flint J.BSR StandardsAudit and Guidelines Working GroupBritish society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.Rheumatology2023;62:e48-88

[31] Fanouriakis A,Alunno A.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.Ann Rheum Dis2019;78:736-45

[32] Gordon C,Gayed M.British Society for Rheumatology StandardsAudit and Guidelines Working GroupThe British society for rheumatology guideline for the management of systemic lupus erythematosus in adults.Rheumatology2018;57:e1-45

[33] Hahn BH,Wilkinson A.American College of RheumatologyAmerican college of rheumatology guidelines for screening, treatment, and management of lupus nephritis.Arthritis Care Res2012;64:797-808 PMCID:PMC3437757

[34] Pons-Estel BA,Soriano ER.Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR)First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American group for the study of lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American league of associations of rheumatology (PANLAR).Ann Rheum Dis2018;77:1549-57

[35] Willis R,McGwin G Jr.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.Lupus2012;21:830-5 PMCID:PMC3808832

[36] Alarcón GS,Bertoli AM.LUMINA Study GroupEffect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).Ann Rheum Dis2007;66:1168-72

[37] Costedoat-Chalumeau N,Aumaître O.Group PLUSHydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).Ann Rheum Dis2013;72:1786-92

[38] Miyagawa I,Nakayamada S.The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.Int J Rheum Dis2020;23:549-58

[39] Petri M,Fang H.Predictors of organ damage in systemic lupus erythematosus: the Hopkins lupus cohort.Arthritis Rheum2012;64:4021-8 PMCID:PMC3510359

[40] Pons-Estel GJ,González LA.Lumina Study GroupPossible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.Arthritis Care Res2010;62:393-400

[41] Rosa GPD,Teixeira A,Cervera R.Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995-2015) from a single referral centre in Catalonia.Lupus2019;28:1158-66

[42] Petri M.Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.Curr Rheumatol Rep2011;13:77-80

[43] Ruiz-Irastorza G,Pijoan JI.Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.Lupus2006;15:577-83

[44] Lakshminarayanan S,Mohanraj M.Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.J Rheumatol2001;28:102-8

[45] Calvo-Alén J,Toloza S.LUMINA Study GroupSystemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.Ann Rheum Dis2006;65:785-90

[46] Li XB,Chu XJ.Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.Ann Med2021;53:1687-95 PMCID:PMC8462850

[47] James JA,Bruner BF.Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.Lupus2007;16:401-9

[48] Pons-Estel GJ,Hachuel L.GLADELAnti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort.Rheumatology2012;51:1293-8 PMCID:PMC3380245

[49] Yokogawa N,Tanikawa A.Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial.Arthritis Rheumatol2017;69:791-9

[50] Chasset F,Costedoat-Chalumeau N,Bessis D.The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study.J Am Acad Dermatol2016;74:693-9.e3

[51] Chung HS.Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine.J Dermatol1997;24:569-72

[52] Pons-Estel GJ,McGwin G Jr.Lumina Study GroupProtective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.Arthritis Rheum2009;61:830-9 PMCID:PMC2898742

[53] Lee JS,Kim YG,Yoo B.Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine.Lupus2020;29:52-7

[54] Clowse ME,Witter F.Hydroxychloroquine in lupus pregnancy.Arthritis Rheum2006;54:3640-7

[55] Cortés-Hernández J,Paredes F,Castillo F.Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies.Rheumatology2002;41:643-50

[56] Koh JH,Kwok SK,Park SH.Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.Lupus2015;24:210-7

[57] Saavedra MÁ,Lara-Mejía A.Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study.Int J Rheum Dis2020;23:633-40

[58] Seo MR,Kim YM.Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.Lupus2019;28:722-30

[59] Balevic SJ,Eudy AM,Schanberg LE.Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes.J Rheumatol2019;46:57-63 PMCID:PMC6314916

[60] Izmirly PM,Pisoni CN.Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.Circulation2012;126:76-82 PMCID:PMC3437628

[61] Rheumatoid arthritis in adults: management. NICE guidelines. Available from: https://www.nice.org.uk/guidance/ng100 [Last accessed on 27 Feb 2024].

[62] Smolen JS,Bergstra SA.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.Ann Rheum Dis2023;82:3-18

[63] Fraenkel L,England BR.2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis.Arthritis Rheumatol2021;73:1108-23

[64] Schapink L,Gevers LAHA,den Broeder AA.The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients.Rheumatology2019;58:131-4

[65] Klarenbeek NB,van der Kooij SM.The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.Ann Rheum Dis2011;70:1039-46

[66] Carmichael SJ,Day RO.Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.J Rheumatol2002;29:2077-83.

[67] Rempenault C,Barnetche T.Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.Ann Rheum Dis2018;77:98-103

[68] Nazir AM,Gupta K.Evaluating the use of hydroxychloroquine in treating patients with rheumatoid arthritis.Cureus2021;13:e19308 PMCID:PMC8575345

[69] Makol A,Wetter DA,Matteson EL.Vasculitis associated with rheumatoid arthritis: a case-control study.Rheumatology2014;53:890-9 PMCID:PMC3999374

[70] Makol A,Warrington KJ.Rheumatoid vasculitis: an update.Curr Opin Rheumatol2015;27:63-70

[71] Wu CL,Kor CT.Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis.Clin J Am Soc Nephrol2018;13:702-9 PMCID:PMC5969483

[72] Casian A,D'Cruz DP.New use for an old treatment: hydroxychloroquine as a potential treatment for systemic vasculitis.Autoimmun Rev2018;17:660-4

[73] Fox R.Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.Lupus1996;5 Suppl 1:S4-10

[74] So A,Joosten LAB.Targeting inflammasomes in rheumatic diseases..Nat Rev Rheumatol2013;9:391-9

[75] Hamzaoui K.Vasculitis and the NLRP3 inflammasome.Curr Opin Rheumatol2024;36:9-15

[76] Tashiro M,Watanabe R.IL-1β promotes tubulointerstitial injury in MPO-ANCA-associated glomerulonephritis.Clin Nephrol2016;86:190-9

[77] Wang LY,Chen M.The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis.J Transl Med2019;17:197 PMCID:PMC6560890

[78] Fujita Y,Temmoku J.Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils.Arthritis Res Ther2019;21:250 PMCID:PMC6880583

[79] Lucchesi A,Musuraca G.Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.J Med Virol2021;93:124-6 PMCID:PMC7361389

[80] Smulski CR.BAFF and BAFF-receptor in B cell selection and survival.Front Immunol2018;9:2285 PMCID:PMC6186824

[81] Krumbholz M,Wick M,Jenne D.BAFF is elevated in serum of patients with Wegener's granulomatosis.J Autoimmun2005;25:298-302

[82] Nagai M,Ebihara I,Kobayashi M.Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity.Nephron Clin Pract2011;118:c339-45

[83] Mumcu G,Yilmaz N.Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome.Oral Health Prev Dent2013;11:229-34

[84] Lambers WM,Bootsma H.Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus.J Rheumatol2021;48:847-51

[85] Mahdy AA,El-fishawy HS.Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients.Bull Fac Pharm Cairo Univ2014;52:37-43

[86] Lepse N,Rutgers A.Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro.Rheumatology2016;55:162-72

[87] O'Sullivan KM,Longano A,Holdsworth SR.Intrarenal Toll-like receptor 4 and Toll-like receptor 2 expression correlates with injury in antineutrophil cytoplasmic antibody-associated vasculitis.Am J Physiol Renal Physiol2018;315:F1283-94 PMCID:PMC6293285

[88] Wang H,Zhao MH.The expression of Toll-like receptors 2, 4 and 9 in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Clin Exp Immunol2014;177:603-10 PMCID:PMC4137844

[89] Holle JU,Lange C,Herlyn K.Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis.Rheumatology2013;52:1183-9

[90] Tadema H,Lepse N,Kallenberg CG.Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission.Rheumatology2011;50:689-96

[91] Hurtado PR,Nitschke J.CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis.BMC Immunol2008;9:34 PMCID:PMC2483256

[92] Konstantinov KN,Tzamaloukas AH.Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms.Autoimmun Rev2015;14:201-3

[93] Husmann CA,Moosig F.Genetics of toll like receptor 9 in ANCA associated vasculitides.Ann Rheum Dis2014;73:890-6

[94] Torigoe M,Ishii A,Nakayamada S.Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.Clin Immunol2018;195:1-7

[95] Cenac C,Guéry JC.Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells.Eur J Immunol2022;52:54-61

[96] Hennessy EJ,O'Neill LA.Targeting Toll-like receptors: emerging therapeutics?.Nat Rev Drug Discov2010;9:293-307

[97] Gao W,Li Q.Inhibition of Toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics.Front Physiol2017;8:508 PMCID:PMC5516312

[98] Hoffmann JC,Dihazi H.Cytokine profiling in anti neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional cohort study.Rheumatol Int2019;39:1907-17 PMCID:PMC7575482

[99] van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.J Rheumatol1997;24:55-60

[100] Wakiya R,Nakashima S.Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.Sci Rep2022;12:10175 PMCID:PMC9205904

[101] Abdulahad WH,Kallenberg CG.T-helper cells as new players in ANCA-associated vasculitides.Arthritis Res Ther2011;13:236 PMCID:PMC3239339

[102] Abdulahad WH,Stegeman CA.Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis.Kidney Int2006;70:938-47

[103] Valenzuela L, Bordignon Draibe J, Fulladosa Oliveras X, Bestard Matamoros O, Cruzado Garrit JM, Torras Ambrós J. T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach.Clin Kidney J2019;12:503-11 PMCID:PMC6671423

[104] Hirayama K,Shimohata H.Analysis of T-cell receptor usage in myeloperoxidase - antineutrophil cytoplasmic antibody-associated renal vasculitis.Clin Exp Nephrol2010;14:36-42

[105] McKinney EF,Jayne DR,Smith KG.T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.Nature2015;523:612-6 PMCID:PMC4623162

[106] Abdulahad WH,van der Geld YM,Limburg PC.Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission.Arthritis Rheum2007;56:2080-91

[107] Kim S,Nel L.Defective STAT5 activation and aberrant expression of BCL6 in naive CD4 T cells enhances follicular Th cell-like differentiation in patients with granulomatosis with polyangiitis.J Immunol2022;208:807-18

[108] Goldman FD,Hollenback C,Premack BA.Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.Blood2000;95:3460-6

[109] van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S. Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells.J Allergy Clin Immunol2013;131:1443-6.e1 PMCID:PMC3955204

[110] Kowatsch MM,Mwangi L.Hydroxychloroquine reduces T cells activation recall antigen responses.PLoS One2023;18:e0287738 PMCID:PMC10395872

[111] Kim ML,Edgington-Mitchell LE.Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells.iScience2021;24:103509 PMCID:PMC8661543

[112] Taverna S,Ferraro M.High mobility group box 1: biological functions and relevance in oxidative stress related chronic diseases.Cells2022;11:849 PMCID:PMC8909428

[113] Guan H,Ma K.The comprehensive role of high mobility group box 1 (HMGB1) protein in different tumors: a pan-cancer analysis.J Inflamm Res2023;16:617-37 PMCID:PMC9938709

[114] Kianian F,Sadeghipour HR,Seifi B.An overview of high-mobility group box 1, a potent pro-inflammatory cytokine in asthma.J Basic Clin Physiol Pharmacol2020;31

[115] Mo J,Cheng X.The role of high mobility group box 1 in neuroinflammatory related diseases.Biomed Pharmacother2023;161:114541

[116] Ge Y,Yao YM.The Effect and regulatory mechanism of high mobility group box-1 protein on immune cells in inflammatory diseases.Cells2021;10:1044 PMCID:PMC8145631

[117] Gou X,Yue Y.The roles of high mobility group box 1 in cerebral ischemic injury.Front Cell Neurosci2020;14:600280 PMCID:PMC7770223

[118] Vijayakumar EC,Prabhavalkar KS.High mobility group box-1 (HMGB1): a potential target in therapeutics.Curr Drug Targets2019;20:1474-85

[119] Bruchfeld A,Bratt J.High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations.Mol Med2011;17:29-35 PMCID:PMC3022976

[120] Wang C,Westra J.Emerging role of high mobility group box 1 in ANCA-associated vasculitis.Autoimmun Rev2015;14:1057-65

[121] Wang C,Chang DY,Zhao MH.Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis.Arthritis Care Res2013;65:1828-34

[122] Wibisono D,Lamprecht P,Gross WL.Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis.Ann Rheum Dis2010;69:1888-9

[123] de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis.Autoimmun Rev2012;11:909-17

[124] Niemann B,Stout C,Boone BA.Biologic functions of hydroxychloroquine in disease: from COVID-19 to Cancer.Pharmaceutics2022;14:2551 PMCID:PMC9787624

[125] Yang M,Xie M.Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis.Biochem Pharmacol2013;86:410-8 PMCID:PMC3713089

[126] Laronha H.Structure and function of human matrix metalloproteinases.Cells2020;9:1076 PMCID:PMC7290392

[127] Nagase H,Murphy G.Structure and function of matrix metalloproteinases and TIMPs.Cardiovasc Res2006;69:562-73

[128] Cabral-Pacheco GA,Castruita-De la Rosa C.The roles of matrix metalloproteinases and their inhibitors in human diseases.Int J Mol Sci2020;21:9739 PMCID:PMC7767220

[129] Zakiyanov O,Hrušková Z.Matrix metalloproteinases and their tissue inhibitors: an evaluation of novel biomarkers in ANCA-associated vasculitis.Fol Biol2019;65:227-36

[130] Sanders JS,Hanemaaijer R,Kallenberg CG.Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis.Am J Physiol Renal Physiol2007;293:F1927-34

[131] Ishizaki J,Horie K.Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of HealthLabour and Welfare of JapanUsefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Res Ther2021;23:91 PMCID:PMC7980538

[132] Rymarz A,Niemczyk S.The significance of metalloproteinase 3 (MMP-3), chemokine CXC ligand 13 (CXCL-13) and complement component C5a in different stages of ANCA associated vasculitis.Sci Rep2021;11:5132 PMCID:PMC7933137

[133] Lesiak A,Sysa-Jedrzejowska A,McCauliffe DP.Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus.Lupus2010;19:683-8

[134] Ertugrul G,Oktay G.Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity.Arch Dermatol Res2018;310:173-9

[135] Merkel PA,Holbrook JT.Wegener's Granulomatosis Etanercept Trial Research GroupBrief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's clinical occurrence of thrombosis (WeCLOT) study.Ann Intern Med2005;142:620-6

[136] Liapi M,Merkel PA,Mohammad AJ.Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study.Rheumatology2021;60:4616-23

[137] Hilhorst M,Wilde B,ten Cate H.Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable.J Rheumatol2013;40:2042-6

[138] Hansrivijit P,Gadhiya KP.Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.Clin Rheumatol2021;40:2843-53

[139] Isaacs B,Antiochos B,Geetha D.Venous thrombotic events in ANCA-Associated vasculitis: incidence and risk factors.Kidney3602020;1:258-62 PMCID:PMC8809268

[140] Carter AE,Perrett RD.Prevention of postoperative deep venous thrombosis and pulmonary embolism.Br Med J1971;1:312-4 PMCID:PMC1794857

[141] Hansen E,Lindewald H,Olesen T.Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine.J Bone Joint Surg Am1976;58:1089-93

[142] Mekinian A,Kuzenko A.SNFMI and the European Forum on Antiphospholipid AntibodiesThe efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study.Autoimmun Rev2015;14:498-502

[143] Belizna C.Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.Autoimmun Rev2015;14:358-62

[144] Espinola R,Ghara A.Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.Thromb Haemost2002;87:518-22

[145] Belizna CC,Thuillez C,Shoenfeld Y.Insights into atherosclerosis therapy in antiphospholipid syndrome.Autoimmun Rev2007;7:46-51

[146] Nuri E,Andreoli L.Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.Immunol Res2017;65:17-24

[147] Erkan D,Peterson MG,Lockshin MD.A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.Rheumatology2002;41:924-9

[148] Rand JH,Quinn AS.Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.Blood2010;115:2292-9 PMCID:PMC2844013

[149] Wu XX,Rand JH.Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.Am J Obstet Gynecol2011;205:576.e7-14 PMCID:PMC3224185

[150] Bengtsson C,Edvinsson L,Sturfelt G.Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus.Basic Clin Pharmacol Toxicol2010;107:919-24

[151] Tanay A,Frayman A,Shargorodsky M.Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment.Ann N Y Acad Sci2007;1108:24-34

[152] Folci M,Shiffer D,Agosti M.ANCA-Associated vasculitides and hematologic malignancies: lessons from the past and future perspectives.J Immunol Res2019;2019:1732175 PMCID:PMC6526571

[153] Heijl C,Flossmann O.European Vasculitis Study Group (EUVAS)Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European vasculitis study group clinical trials.Ann Rheum Dis2011;70:1415-21

[154] Mahr A,Le Guenno G.ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships.Best Pract Res Clin Rheumatol2013;27:45-56

[155] van Daalen EE,Kronbichler A.Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.Ann Rheum Dis2017;76:1064-9

[156] Geser A,Draper CC.Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma.Am J Epidemiol1989;129:740-52

[157] Gheitasi H,Solans R.SS Study GroupAutoimmune Diseases Study Group (GEAS)Spanish Society of Internal Medicine (SEMI)How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients.Int Immunopharmacol2015;27:194-9

[158] Ko KM.Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea.Korean J Intern Med2023;38:113-24 PMCID:PMC9816677

[159] Lee H,Gautam N.Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.Clin Exp Rheumatol2023;41:110-7 PMCID:PMC9652105

[160] Houben E,Voskuyl AE.Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.Rheumatology2018;57:555-62

[161] Massicotte-Azarniouch D,Walsh M.Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study.Clin Kidney J2022;15:681-92 PMCID:PMC9022464

[162] Raza K,Townend JN.Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease?.Circulation2000;102:1470-2

[163] Booth AD,Kharbanda RK.Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.Circulation2004;109:1718-23

[164] Clifford AH.Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis.Atherosclerosis2021;325:8-15

[165] Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides.Best Pract Res Clin Rheumatol2013;27:33-44

[166] Penn SK,Schott LL.Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.J Rheumatol2010;37:1136-42 PMCID:PMC3457696

[167] Petri M.Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.Lupus1996;5:16-22

[168] Solomon DH,Lu B.Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.Arthritis Care Res2014;66:1246-51 PMCID:PMC4467535

[169] Petri M,Magder L.Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis.Am J Med1994;96:254-9

[170] Xu T,Jiang M.Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening.RMD Open2022;8:e002424 PMCID:PMC9594583

[171] Flossmann O,de Groot K.European Vasculitis Study GroupLong-term patient survival in ANCA-associated vasculitis.Ann Rheum Dis2011;70:488-94

[172] Ruiz-Irastorza G,Ruiz-Arruza I,Egurbide MV.Predictors of major infections in systemic lupus erythematosus.Arthritis Res Ther2009;11:R109 PMCID:PMC2745791

[173] Smitten AL,Hochberg MC.The risk of hospitalized infection in patients with rheumatoid arthritis.J Rheumatol2008;35:387-93.

[174] Yusuf IH,Lotery AJ.The royal college of ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary.Eye2021;35:1532-7 PMCID:PMC8169737

[175] Learoyd AE,Reid F.HAVEN study groupThe HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.Trials2023;24:261 PMCID:PMC10077754

[176] Price EJ,Tappuni AR.British Society for Rheumatology StandardsGuideline and Audit Working GroupThe British society for rheumatology guideline for the management of adults with primary Sjögren's syndrome.Rheumatology2017;56:e24-48

[177] Ramos-Casals M,Bombardieri S.EULAR-Sjögren Syndrome Task Force GroupEULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.Ann Rheum Dis2020;79:3-18

[178] Fox R,Guarrasi V.Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.Lupus1996;5:31-6

[179] Cankaya H,Karabulut G,Boyacioglu H.Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study.Oral Surg Oral Med Oral Pathol Oral Radiol Endod2010;110:62-7

[180] Kruize AA,Kallenberg CG.Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial.Ann Rheum Dis1993;52:360-4 PMCID:PMC1005050

[181] Fox RI,Benton L,Friedlaender M.Treatment of primary Sjögren's syndrome with hydroxychloroquine.Am J Med1988;85:62-7

[182] Yoon CH,Lee EY.Effect of hydroxychloroquine treatment on dry eyes in subjects with primary sjögren's syndrome: a double-blind randomized control study.J Korean Med Sci2016;31:1127-35 PMCID:PMC4901007

[183] Gottenberg JE,Puéchal X.Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.JAMA2014;312:249-58

[184] Wang SQ,Wei P.Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.BMC Musculoskelet Disord2017;18:186 PMCID:PMC5427554

[185] Tektonidou MG,Limper M.EULAR recommendations for the management of antiphospholipid syndrome in adults.Ann Rheum Dis2019;78:1296-304

[186] Erkan D,Sciascia S.APS ACTIONHydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.Lupus2018;27:399-406

[187] Sciascia S,Talavera-Garcia E,Khamashta MA.The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.Am J Obstet Gynecol2016;214:273.e1-8

[188] Hooper A,Bedaiwy MA.Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review.Am J Reprod Immunol2023;90:e13761

[189] Edwards MH,Liu X,Anderson G.Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice.Circulation1997;96:4380-4

[190] Baughman RP,Korsten P.ERS clinical practice guidelines on treatment of sarcoidosis.Eur Respir J2021;58:2004079

[191] Thillai M,Crawshaw A.BTS clinical statement on pulmonary sarcoidosis.Thorax2021;76:4-20

[192] Smedslund G,Uhlig T.Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments.Rheumatol Int2022;42:2109-24 PMCID:PMC9548475

[193] Sharma R,Mohan A.Treatment of pulmonary sarcoidosis with hydroxycholoroquine: result of a pilot study from Indi.Chest2003;124:109S

[194] Ben Hassine I,Comarmond C.Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients.Joint Bone Spine2019;86:789-93

[195] Sharma OP.Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.Arch Neurol1998;55:1248-54

[196] Lee W,Boxma-de Klerk B.Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial.Arthritis Care Res2018;70:1320-5

[197] Kingsbury SR,Keding A.Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial.Ann Intern Med2018;168:385-95

[198] Wright NA,Patel M,Femia AN.Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers.JAMA Dermatol2016;152:97-9

[199] Woo TY,Voorhees JJ,Hanno R.Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.J Am Acad Dermatol1984;10:592-600

[200] Zhang QC,Chen ZX,Lin CS.Case report: treatment of anti-MDA5-positive amyopathic dermatomyositis accompanied by a rapidly progressive interstitial lung diseases with methylprednisolone pulse therapy combined with cyclosporine A and hydroxychloroquine.Front Med2020;7:610554 PMCID:PMC7732655

[201] Olson NY.Adjunctive use of hydroxychloroquine in childhood dermatomyositis.J Rheumatol1989;16:1545-7.

[202] Lin YC,Nong BR.Pediatric Kikuchi-Fujimoto disease: a clinicopathologic study and the therapeutic effects of hydroxychloroquine.J Microbiol Immunol Infect2019;52:395-401

[203] Hyun M,Kim HA,Ryu SY.Recurrent Kikuchi's disease treated by hydroxychloroquine.Infect Chemother2016;48:127-31 PMCID:PMC4945722

[204] Sun L,Chen Q.Application and safety of hydroxychloroquine in chronic disease among children.Zhonghua Er Ke Za Zhi2021;59:107-12

[205] Nogueira IA,Henn GAL.Hydroxychloroquine for the management of chronic chikungunya arthritis.Rev Inst Med Trop Sao Paulo2023;65:e26 PMCID:PMC10115449

[206] Mohammadpour F,Hadjibabaie M.The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: a review of the literature.J Res Pharm Pract2018;7:4-12 PMCID:PMC5934986

[207] Bockow B.Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports.J Med Case Rep2013;7:91 PMCID:PMC3623781

[208] Zhang J,Feng J,Wang S.Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a systematic review and meta-analysis.Biomed Res Int2021;2021:9171715 PMCID:PMC8664532

[209] Liu LJ,Shi SF.Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial.Am J Kidney Dis2019;74:15-22

[210] Si FL,Lv JC.Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study.BMC Nephrol2023;24:175 PMCID:PMC10268518

[211] WHO guidelines for malaria. Available from https://www.who.int/publications/i/item/guidelines-for-malaria [Last accessed on 27 Feb 2024].

[212] Horby P,Linsell L.RECOVERY Collaborative GroupEffect of hydroxychloroquine in hospitalized patients with Covid-19.N Engl J Med2020;383:2030-40 PMCID:PMC7556338

[213] Arabi YM,Derde LPG.REMAP-CAP InvestigatorsLopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.Intensive Care Med2021;47:867-86

[214] Sivapalan P,Lapperre TS.ProPAC-COVID writing group on behalf of the ProPAC-COVID Study GroupAzithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial.Eur Respir J2022;59:2100752 PMCID:PMC8186006

[215] Pan H,Henao-Restrepo AM.WHO Solidarity Trial ConsortiumRepurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results.N Engl J Med2021;384:497-511 PMCID:PMC7727327

[216] Pradelle A,Provencher S,Grenet G.Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate.Biomed Pharmacother2024;171:116055

[217] Diagnosis and management of Q fever - United States, 2013: recommendations from CDC and the Q fever working group. Available from: https:// www.cdc.gov/mmwr/preview/mmwrhtml/rr6203a1.htm [Last accessed on 27 Feb 2024].

[218] Coxiella burnetii infection. BMJ Best Practice Available from: https://bestpractice.bmj.com/topics/en-gb/1139 [Last accessed on 27 Feb 2024].

[219] Whipple’s disease. BMJ Best Practice Available from: https://bestpractice.bmj.com/topics/en-gb/467 [Last accessed on 27 Feb 2024].

[220] Wang X,Jia S.In vitro and in vivo synergistic effects of hydroxychloroquine and itraconazole on Cryptococcus neoformans.Folia Microbiol2023;68:595-605

[221] Luo W,Lu H.New perspectives from misdiagnosis: a case of primary cutaneous cryptococcosis treated with hydroxychloroquine sulfate successfully.Mycopathologia2020;185:595-6 PMCID:PMC7231481

[222] Rolain JM,Raoult D.Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.Int J Antimicrob Agents2007;30:297-308 PMCID:PMC7126847

[223] Dias-Melicio LA,Calvi SA.Chloroquine inhibits paracoccidioides brasiliensis survival within human monocytes by limiting the availability of intracellular iron.Microbiol Immunol2006;50:307-14

[224] Naghipour S,Rahsepar S.Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.Expert Rev Anti Infect Ther2020;18:1119-33

[225] Shiryaev SA,Pinto A.Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis.Sci Rep2017;7:15771 PMCID:PMC5694003

[226] Hamilton BK.Updates in chronic graft-versus-host disease.Hematol Am Soc Hematol Educ Program2021;2021:648-54 PMCID:PMC8791178

[227] Gilman AL,Mogul A.Hydroxychloroquine for the treatment of chronic graft-versus-host disease.Biol Blood Marrow Transplant2000;6:327-34

[228] Khoury H,Zhang MJ.Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation.Biol Blood Marrow Transplant2003;9:714-21

[229] Fong T,Adkins D.A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.Biol Blood Marrow Transplant2007;13:1201-6

[230] Gilman AL,Goldman FD.Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a children's oncology group study.Biol Blood Marrow Transplant2012;18:84-91 PMCID:PMC4627789

[231] Lagneaux L,Dejeneffe M,Bernier M.Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio.Leuk Lymphoma2002;43:1087-95

[232] Mansilla E,Nuñez L.The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro.Cancer Biother Radiopharm2010;25:97-103

[233] Jiang PD,Shi W.Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37.Cell Physiol Biochem2008;22:431-40

[234] Rahim R.Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.Anticancer Drugs2009;20:736-45

[235] Singal AK.Porphyria cutanea tarda: recent update.Mol Genet Metab2019;128:271-81

[236] Cainelli T,Marchesi L.Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda.Br J Dermatol1983;108:593-600

[237] Marchesi L,Cainelli T.A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients.Photodermatology1984;1:286-92

[238] Singal AK,Lee C.Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.Clin Gastroenterol Hepatol2012;10:1402-9 PMCID:PMC3501544

[239] Pareek A,Sacchidanand S,Naik GS.Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study.Indian J Dermatol Venereol Leprol2008;74:18-22

[240] Hrin ML,Huang WW.Hydroxychloroquine for generalized granuloma annulare: 35% response rate in a retrospective case series of 26 patients.J Am Acad Dermatol2022;87:144-7

[241] Eisen D.Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial.J Am Acad Dermatol1993;28:609-12

[242] Husein-ElAhmed H,Steinhoff M.Lichen planus: a comprehensive evidence-based analysis of medical treatment.J Eur Acad Dermatol Venereol2019;33:1847-62

[243] Stoopler ET,Alawi F.Novel combination therapy of hydroxychloroquine and topical tacrolimus for chronic ulcerative stomatitis.Int J Dermatol2021;60:e162-3

[244] Brant EG.Hydroxychloroquine for the treatment of hidradenitis suppurativa.JAAD Case Rep2023;37:64-7 PMCID:PMC10275947

[245] Khan N,DuBuske I,Bernstein DI.Effectiveness of hydroxychloroquine and omalizumab in chronic spontaneous urticaria: a real-world study.J Allergy Clin Immunol Pract2022;10:3300-5

[246] Reeves GE,Bonfield J,Loewenthal M.Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation.Intern Med J2004;34:182-6

[247] Koch MW,Sage K.Hydroxychloroquine for primary progressive multiple sclerosis.Ann Neurol2021;90:940-8

[248] Sun L,Zhang J.Hydroxychloroquine ameliorates hematuria in children with X-linked alport syndrome: retrospective case series study.Pharmgenomics Pers Med2023;16:145-51 PMCID:PMC9976585

[249] Plantone D.Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review.Clin Drug Investig2018;38:653-71

[250] Guennec P, Dromer C, Sixou L, Marc V, Coustals P, Fournié B. Treatment of horton disease. value of synthetic antimalarials. apropos of a retrospective study of 36 patients.Rev Rhum Ed Fr1994;61:485-90.

[251] Hydroxychloroquine in giant cell arteritis. Available from: https://classic.clinicaltrials.gov/ct2/show/record/NCT00430807 [Last accessed on 27 Feb 2024].

[252] Rongyi C,Jiang L.Effect of hydroxychloroquine on angiographic progression in routine treatment of takayasu arteritis.Mod Rheumatol2021;31:1135-41

[253] Casian A,D'cruz D.AB0531 the role of hydroxychloroquine in ANCA positive and negative vasculitis.Ann Rheum Dis2016;75:1086-7

[254] Papachristodoulou E,Tiniakou E.Therapeutic options for cutaneous polyarteritis nodosa: a systematic review.Rheumatology2021;60:4039-47

[255] Panda PK,Natarajan V,Panda P.COVID-19 treatment in children: a systematic review and meta-analysis.J Family Med Prim Care2021;10:3292-302 PMCID:PMC8565105

[256] Kolkhir P,Bonnekoh H,Maurer M.Treatment of urticarial vasculitis: a systematic review.J Allergy Clin Immunol2019;143:458-66

[257] Bostan E,Gokoz O.Rapid response to combination of hydroxychloroquine and prednisolone in a patient with refractory hypocomplementemic urticarial vasculitis.Dermatol Ther2020;33:e14531

[258] Lopez LR,Kohler PF.The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine.J Allergy Clin Immunol1984;73:600-3

[259] Batioğlu F,Aydintuğ OT,Ozmert E.Recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis.Cutan Ocul Toxicol2006;25:281-5

[260] Farkas H,Bély M.Angiooedema due to acquired deficiency of C1-esterase inhibitor associated with leucocytoclastic vasculitis.Acta Derm Venereol2001;81:298-300

[261] Jachiet M,Deroux A.French Vasculitis Study GroupThe clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients.Arthritis Rheumatol2015;67:527-34

[262] Basnet A.Hemophagocytic lymphohistiocytosis in a patient with goodpasture's syndrome: a rare clinical association.Am J Case Rep2014;15:431-6 PMCID:PMC4199464

[263] Oh MJ,Kwon NH.Churg-Strauss syndrome: the clinical features and long-term follow-up of 17 patients.J Korean Med Sci2006;21:265-71 PMCID:PMC2734002